Compare IBOC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBOC | ERAS |
|---|---|---|
| Founded | 1966 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | 1995 | 2021 |
| Metric | IBOC | ERAS |
|---|---|---|
| Price | $75.79 | $19.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $87.00 | $14.25 |
| AVG Volume (30 Days) | 366.0K | ★ 5.6M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | 0.76 | ★ 36.23 |
| EPS | ★ 1.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.20 | $1.33 |
| 52 Week High | $78.46 | $24.28 |
| Indicator | IBOC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 61.80 |
| Support Level | $74.39 | $17.63 |
| Resistance Level | $77.11 | $21.60 |
| Average True Range (ATR) | 1.26 | 1.31 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 39.48 | 57.11 |
International Bancshares Corp is a registered multibank financial holding company providing a diversified range of commercial and retail banking services in its main banking and branch facilities located in north, south, central, and southeast Texas and the State of Oklahoma.. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.